A patient's response to therapy and risk of recurrence can be assessed by regular monitoring of the tumor markers [8]. The use of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) is not extensively explored in our setting. This evidence concerns the gene CEACAM5 and cancer.